Nikolaos Grigoriadis

List of Publications by Year
in descending order

128 papers	3,277 citations	159585 30 h-index	189892 50 g-index
130 all docs	130 docs citations	130 times ranked	4608 citing authors

#	Article	IF	Citations
1	Novel ADNP Syndrome Mice Reveal Dramatic Sex-Specific Peripheral Gene Expression With Brain Synaptic and Tau Pathologies. Biological Psychiatry, 2022, 92, 81-95.	1.3	32
2	Lumbar spine intrathecal transplantation of neural precursor cells promotes oligodendrocyte proliferation in hot spots of chronic demyelination. Brain Pathology, 2022, 32, e13040.	4.1	7
3	Novel contributors to B cell activation during inflammatory CNS demyelination; An oNGOing process. International Journal of Medical Sciences, 2022, 19, 164-174.	2.5	1
4	Teaching NeuroImage: Carotid Web: A Thrombogenic Nest Not to Miss. Neurology, 2022, , 10.1212/WNL.0000000000013321.	1.1	1
5	Neuropsychological correlates of cerebellar volumes in multiple sclerosis: an MRI volumetric analysis study. Journal of Integrative Neuroscience, 2022, 21, 013.	1.7	4
6	Neurological manifestations of long-COVID syndrome: a narrative review. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232210768.	2.5	120
7	Psychopharmacology of patients with multiple sclerosis in Greece during the period 2017-2019. Psychiatrikē = Psychiatriki, 2022, , .	0.6	0
8	The Role of Diet and Interventions on Multiple Sclerosis: A Review. Nutrients, 2022, 14, 1150.	4.1	52
9	What scans see when patients see defects: neuroimaging findings in body dysmorphic disorder. Journal of Integrative Neuroscience, 2022, 21, 045.	1.7	2
10	Comparison of the Greek Version of the Quick Mild Cognitive Impairment Screen and Montreal Cognitive Assessment in Older Adults. Healthcare (Switzerland), 2022, 10, 906.	2.0	2
11	Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response. Cells, 2022, 11, 1959.	4.1	3
12	Symbol Digit Modalities Test: Greek Normative Data for the Oral and Written Version and Discriminative Validity in Patients with Multiple Sclerosis. Archives of Clinical Neuropsychology, 2021, 36, 117-125.	0.5	9
13	Tongue strength, dysphagia questionnaire, pharyngeal secretions and FEES findings in dysphagia management in amyotrophic lateral sclerosis. Auris Nasus Larynx, 2021, 48, 672-682.	1.2	18
14	Continuous and interval training attenuate encephalomyelitis by separate immunomodulatory mechanisms. Annals of Clinical and Translational Neurology, 2021, 8, 190-200.	3.7	11
15	Off-label intravenous thrombolysis for early recurrent brain embolism associated with aortic arch thrombus. Neurological Research and Practice, 2021, 3, 4.	2.0	0
16	Persistent decline of hospitalizations for acute stroke and acute coronary syndrome during the second wave of the COVID-19 pandemic in Greece: collateral damage unaffected. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110295.	3.5	12
17	High-Intensity Exercise Training Protects the Brain Against Autoimmune Neuroinflammation: Regulation of Microglial Redox and Pro-inflammatory Functions. Frontiers in Cellular Neuroscience, 2021, 15, 640724.	3.7	22
18	Primary progression in NMOSD. Does it really exist?. Multiple Sclerosis and Related Disorders, 2021, 48, 102712.	2.0	2

#	Article	IF	Citations
19	B-cells expressing NgR1 and NgR3 are localized to EAE-induced inflammatory infiltrates and are stimulated by BAFF. Scientific Reports, 2021, 11, 2890.	3.3	11
20	Novel frameshift variant of NHLRC1 gene in compound heterozygosity in an adult Greek patient with Lafora disease. Seizure: the Journal of the British Epilepsy Association, 2021, 86, 49-51.	2.0	1
21	The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis. Neurochemistry International, 2021, 144, 104938.	3.8	9
22	Hereditary diffuse leukoencephalopathy with spheroids mimicking primary progressive aphasia: report of a Greek case. Neurological Sciences, 2021, 42, 3431-3433.	1.9	3
23	Brief international cognitive assessment for multiple sclerosis (BICAMS) cut-off scores for detecting cognitive impairment in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 49, 102751.	2.0	8
24	Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders. Metabolism: Clinical and Experimental, 2021, 118, 154736.	3.4	6
25	Serotoninergic system targeting in multiple sclerosis: the prospective for pathogenetic therapy.. Multiple Sclerosis and Related Disorders, 2021, 51, 102888.	2.0	15
26	Progressive multifocal leukoencephalopathy in an elderly immunocompetent-appearing patient: Relevance with L-selectin (CD62L) expression and immunosenescence. Clinical Neurology and Neurosurgery, 2021, 205, 106625.	1.4	5
27	A Greek Validation Study of the Multiple Sclerosis Work Difficulties Questionnaire-23. Healthcare (Switzerland), 2021, 9, 897.	2.0	3
28	Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center. Frontiers in Neurology, 2021, 12, 699844.	2.4	5
29	Spastic gait, intellectual disability and seizures due to a rare mutation causing hyperargininemia. Clinical Neurology and Neurosurgery, 2021, 208, 106895.	1.4	1
30	Oxidative Stress and Neurodegeneration: Interconnected Processes in PolyQ Diseases. Antioxidants, 2021, 10, 1450.	5.1	17
31	Signaling through the S1Pâ^'S1PR Axis in the Gut, the Immune and the Central Nervous System in Multiple Sclerosis: Implication for Pathogenesis and Treatment. Cells, 2021, 10, 3217.	4.1	9
32	A National Representative, Cross-Sectional Study by the Hellenic Academy of NeuroImmunology (HEL.A.NI.) on COVID-19 and Multiple Sclerosis: Overall Impact and Willingness Toward Vaccination. Frontiers in Neurology, 2021, 12, 757038.	2.4	3
33	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	1.0	3
34	Dysphagia Prevalence, Attitudes, and Related Quality of Life in Patients with Multiple Sclerosis. Dysphagia, 2020, 35, 677-684.	1.8	18
35	Potential impact of Helicobacter pylori-related Galectin-3 on chronic kidney, cardiovascular and brain disorders in decompensated cirrhosis. Digestive and Liver Disease, 2020, 52, 121-123.	0.9	12
36	Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial. Multiple Sclerosis and Related Disorders, 2020, 39, 101932.	2.0	23

#	Article	IF	Citations
37	Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe?. Brain, 2020, 143, e100-e100.	7.6	21
38	The Administrative Prevalence of Multiple Sclerosis in Greece on the Basis of a Nationwide Prescription Database. Frontiers in Neurology, 2020, 11, 1012.	2.4	14
39	Tauopathy in the young autistic brain: novel biomarker and therapeutic target. Translational Psychiatry, 2020, 10, 228.	4.8	57
40	Prevalence of patent foramen ovale in the Greek population is high and impacts on the interpretation of the risk of paradoxical embolism (RoPE) score. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096467.	3.5	7
41	Multiple Sclerosis: Shall We Target CD33?. Genes, 2020, 11, 1334.	2.4	9
42	Biomarkers in Rare Demyelinating Disease of the Central Nervous System. International Journal of Molecular Sciences, 2020, 21, 8409.	4.1	6
43	Application of antibody phage display to identify potential antigenic neural precursor cell proteins. Journal of Biological Research, 2020, 27, 14.	2.1	2
44	Clinically reliable cognitive decline in relapsing remitting multiple sclerosis: Is it the tip of the iceberg?. Neurological Research, 2020, 42, 575-586.	1.3	7
45	Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review. Frontiers in Neurology, 2020, 11, 281.	2.4	76
46	Encephalomyelitis and Lymphadenopathy in a Man in His Early 40s. JAMA Neurology, 2020, 77, 1171.	9.0	0
47	Cognitive Fatigability is Independent of Subjective Cognitive Fatigue and Mood in Multiple Sclerosis. Cognitive and Behavioral Neurology, 2020, 33, 113-121.	0.9	7
48	Neurological manifestations and implications of COVID-19 pandemic. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093203.	3.5	114
49	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sciences, 2020, 10, 345.	2.3	38
50	The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients. Multiple Sclerosis and Related Disorders, 2020, 41, 102047.	2.0	20
51	Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk. Neurological Research, 2020, 42, 209-221.	1.3	5
52	Acute Pain in the Neck: Donâ€™t Miss the Crown!. Neurohospitalist, The, 2020, 10, 318-319.	0.8	1
53	Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know. Brain Sciences, 2020, 10, 234.	2.3	59
54	Spatio-temporal expression profile of NGF and the two-receptor system, TrkA and p75NTR, in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2020, 17, 41.	7.2	17

#	Article	IF	Citations
55	Rodent models of obesity. Minerva Endocrinologica, 2020, 45, 243-263.	1.8	20
56	Computerized cognitive rehabilitation for treatment of cognitive impairment in multiple sclerosis: an explorative study. Journal of Integrative Neuroscience, 2020, 19, 341.	1.7	8
57	Exercise intensityâ€dependent immunomodulatory effects on encephalomyelitis. Annals of Clinical and Translational Neurology, 2019, 6, 1647-1658.	3.7	17
58	TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort. Multiple Sclerosis and Related Disorders, 2019, 35, 116-118.	2.0	8
59	Cognitive and brain reserve in multiple sclerosisâ€“â€“A cross-sectional study. Multiple Sclerosis and Related Disorders, 2019, 35, 128-134.	2.0	17
60	Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmunity Highlights, 2019, 10, 7.	3.9	84
61	â€œRadiologically Isolatedâ€•Spinal Cavernoma Associated with Familial Cerebral Cavernomatosis. European Neurology, 2019, 81, 327-330.	1.4	0
62	The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse. Translational Psychiatry, 2019, 9, 2.	4.8	42
63	Atypical Auditory Brainstem Response and Protein Expression Aberrations Related to ASD and Hearing Loss in the Adnp Haploinsufficient Mouse Brain. Neurochemical Research, 2019, 44, 1494-1507.	3.3	19
64	EEG Window Length Evaluation for the Detection of Alzheimerâ€™s Disease over Different Brain Regions. Brain Sciences, 2019, 9, 81.	2.3	35
65	Analysis of electroencephalographic signals complexity regarding Alzheimer's Disease. Computers and Electrical Engineering, 2019, 76, 198-212.	4.8	35
66	Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate. Journal of the Neurological Sciences, 2019, 401, 43-50.	0.6	5
67	Gene variants of adhesion molecules predispose to MS: A case-control study. Neurology: Genetics, 2019, 5, e304.	1.9	14
68	Comment on: â€œOral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysisâ€• CNS Drugs, 2019, 33, 293-295.	5.9	1
69	Helicobacter pylori infection and gastric cancer biology: tempering a double-edged sword. Cellular and Molecular Life Sciences, 2019, 76, 2477-2486.	5.4	59
70	Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?. Cells, 2019, 8, 1.	4.1	170
71	Replication study of GWAS risk loci in Greek multiple sclerosis patients. Neurological Sciences, 2019, 40, 253-260.	1.9	24
72	Exposure to 3-Nitropropionic Acid Mitochondrial Toxin Induces Tau Pathology in Tangle-Mouse Model and in Wild Type-Mice. Frontiers in Cell and Developmental Biology, 2019, 7, 321.	3.7	12

#	Article	IF	Citations
73	Cyclization of PLP139-151 peptide reduces its encephalitogenic potential in experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2018, 26, 2221-2228.	3.0	7
74	A potential impact of Helicobacter pylori -related galectin-3 in neurodegeneration. Neurochemistry International, 2018, 113, 137-151.	3.8	21
75	p75NTR and TROY: Uncharted Roles of Nogo Receptor Complex in Experimental Autoimmune Encephalomyelitis. Molecular Neurobiology, 2018, 55, 6329-6336.	4.0	8
76	Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 21, 117-119.	2.0	2
77	Exercise training attenuates experimental autoimmune encephalomyelitis by peripheral immunomodulation rather than direct neuroprotection. Experimental Neurology, 2018, 299, 56-64.	4.1	26
78	The Rationale for Monitoring Cognitive Function in Multiple Sclerosis: Practical Issues for Clinicians. The Open Neurology Journal, 2018, 12, 31-40.	0.4	17
79	Estimating Everyday Neuropsychological Functioning in Multiple Sclerosis: Reliability and Validity of the Greek Multiple Sclerosis Neuropsychological Questionnaire. Multiple Sclerosis International, 2018, 2018, 1-6.	0.8	1
80	Reliability and validity of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis (Greek version) and proposed modification. Multiple Sclerosis and Related Disorders, 2018, 23, 62-68.	2.0	13
81	White matter hyperintensities in myotonic dystrophy type 2: Not always another expression of the disease. Multiple Sclerosis and Related Disorders, 2018, 24, 117-119.	2.0	4
82	An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis. Medicinal Chemistry, 2018, 14, 155-169.	1.5	15
83	Helicobacter pylori eradication to prevent cardio-cerebrovascular disease: Are current data useful for clinical practice?. International Journal of Cardiology, 2017, 233, 92.	1.7	4
84	Gene variants of adhesion molecules act as modifiers of disease severity in MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e350.	6.0	15
85	Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Molecular Neurobiology, 2017, 54, 3911-3923.	4.0	33
86	Cyclic MOG 35 â€“ 55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. Bioorganic and Medicinal Chemistry, 2017, 25, 4163-4174.	3.0	11
87	Longâ€term effects of autoimmune CNS inflammation on adult hippocampal neurogenesis. Journal of Neuroscience Research, 2017, 95, 1446-1458.	2.9	19
88	Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. International Journal of Cardiology, 2017, 229, 17-18.	1.7	36
89	Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial. Behavioural Neurology, 2017, 2017, 1-17.	2.1	37
90	Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents. Journal of Neuroinflammation, 2017, 14, 227.	7.2	7

#	Article	IF	Citations
91	Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks. Multiple Sclerosis International, 2016, 2016, 1-8.	0.8	30
92	Nogo receptor complex expression dynamics in the inflammatory foci of central nervous system experimental autoimmune demyelination. Journal of Neuroinflammation, 2016, 13, 265.	7.2	24
93	The Efficacy of Natalizumab versus Fingolimod for Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Indirect Evidence from Randomized Placebo-Controlled Trials and Meta-Analysis of Observational Head-to-Head Trials. PLoS ONE, 2016, 11, e0163296.	2.5	23
94	Health 4.0: The case of multiple sclerosis. , 2016, , .		9
95	Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion. Expert Opinion on Pharmacotherapy, 2016, 17, 2085-2095.	1.8	3
96	Telmisartan-mediated metabolic profile conferred brain protection in diabetic hypertensive rats as evidenced by magnetic resonance imaging, behavioral studies and histology. European Journal of Pharmacology, 2016, 789, 88-97.	3.5	2
97	Immunophenotype of mouse cerebral hemispheres-derived neural precursor cells. Neuroscience Letters, 2016, 611, 33-39.	2.1	3
98	â€œLiberation treatmentâ€•for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free. Brain and Behavior, 2015, 5, 3-12.	2.2	19
99	Subcutaneous Transplantation of Neural Precursor Cells in Experimental Autoimmune Encephalomyelitis Reduces Chemotactic Signals in the Central Nervous System. Stem Cells Translational Medicine, 2015, 4, 1450-1462.	3.3	11
100	Connexin43 and connexin47 alterations after neural precursor cells transplantation in experimental autoimmune encephalomyelitis. Glia, 2015, 63, 1772-1783.	4.9	17
101	The Effect of Disease Modifying Therapies on Brain Atrophy in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0116511.	2.5	37
102	The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0144538.	2.5	31
103	Muscular dystrophy in a patient with multiple sclerosis. Another â€œdouble-troubleâ€?. Multiple Sclerosis and Related Disorders, 2015, 4, 342-344.	2.0	7
104	The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 2015, 8, 193-202.	3.5	24
105	Helicobacter Pylori-Related Vitamin B12 Deficiency: A Potential Contributor in Neuropsychiatric Disorders. Indian Journal of Psychological Medicine, 2015, 37, 475-476.	1.5	3
106	Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1386-1395.	1.9	280
107	A â€˜Posterior Circulation Strokeâ€™ that Benefits from Vitamins. American Journal of Medicine, 2014, 127, e1-e2.	1.5	2
108	Characterization of In Vitro Expanded Bone Marrow-Derived Mesenchymal Stem Cells Isolated from Experimental Autoimmune Encephalomyelitis Mice. Journal of Molecular Neuroscience, 2013, 51, 282-297.	2.3	7

#	Article	IF	Citations
109	Time Course and Spatial Profile of Nogo-A Expression in Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice. Journal of Neuropathology and Experimental Neurology, 2012, 71, 907-920.	1.7	40
110	Time-dependent fate of transplanted neural precursor cells in experimental autoimmune encephalomyelitis mice. Experimental Neurology, 2011, 230, 16-26.	4.1	23
111	Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Experimental Neurology, 2011, 230, 78-89.	4.1	86
112	Five-year Survival After Helicobacter pylori Eradication in Alzheimer Disease Patients. Cognitive and Behavioral Neurology, 2010, 23, 199-204.	0.9	94
113	Helicobacter pylori with or without its neutrophil-activating protein may be the common denominator associated with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2010, 16, 376-377.	3.0	17
114	Transplanted Neural Precursors Enhance Host Brain-Derived Myelin Regeneration. Journal of Neuroscience, 2009, 29, 15694-15702.	3.6	112
115	A concept of Helicobacter pylori and stress-secreted mast cells' potential involvement in brain metastases. Journal of Neuroimmunology, 2009, 209, 121-122.	2.3	18
116	Eradication of Helicobacter pylori may be beneficial in the management of Alzheimerâ€™s disease. Journal of Neurology, 2009, 256, 758-767.	3.6	150
117	From the â€œlittle brainâ€•gastrointestinal infection to the â€œbig brainâ€•neuroinflammation: A proposed fast axonal transport pathway involved in multiple sclerosis. Medical Hypotheses, 2009, 73, 781-787.	1.5	31
118	Helicobacter pylori infection as a risk factor for primary open-angle glaucoma. Clinical and Experimental Ophthalmology, 2008, 36, 196-196.	2.6	12
119	Helicobacter pylori and multiple sclerosis. Journal of Neuroimmunology, 2007, 188, 187-189.	2.3	50
120	Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Experimental Neurology, 2006, 198, 275-284.	4.1	154
121	Neuroinflammation in multiple sclerosis: Evidence for autoimmune dysregulation, not simple autoimmune reaction. Clinical Neurology and Neurosurgery, 2006, 108, 241-244.	1.4	49
122	Titanium dioxide photocatalytic inactivation of prions. Journal of General Virology, 2006, 87, 3125-3130.	2.9	47
123	Virus-mediated autoimmunity in Multiple Sclerosis. Journal of Autoimmune Diseases, 2006, 3, 1.	1.0	33
124	Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics. Current Medicinal Chemistry, 2005, 12, 1513-1519.	2.4	6
125	Recovery, innervation profile, and contractile properties of reinnervating fast muscles following postnatal nerve crush and administration of l-Dopa. Developmental Brain Research, 2004, 153, 79-87.	1.7	6
126	Axonal damage in multiple sclerosis: a complex issue in a complex disease. Clinical Neurology and Neurosurgery, 2004, 106, 211-217.	1.4	44

#	Article	IF	Citations
127	Interferon Î² treatment in relapsingâ€“remitting multiple sclerosis. A review. Clinical Neurology and Neurosurgery, 2002, 104, 251-258.	1.4	17
128	An unusual phenotype of Acute Motor Sensory Axonal Neuropathy with ophthalmoplegia and <scp>antiâ€GD1a</scp> , â€•<scp>GD1b</scp> , â€•<scp>GM1</scp> antibodies. Clinical and Experimental Neuroimmunology, 0, , .	1.0	0